Trivalent arsenic (AsIII) is a clinically approved treatment agent for patients with promyelocytic leukaemia, but cannot be used for other types of leukaemia due to its toxicity. Here the authors show that different patient-derived leukaemia cells express CD71 and design a ferritin-based nanoparticle for specific delivery of AsIII to these cells, demonstrating substantially improved efficacy towards different leukaemia types in animal models, with reduced side effects.
- Changlong Wang
- Wei Zhang
- Ding Ma
